Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ISTA Vitrase Data Subgroup Analysis Could Support Efficacy, Cmte. Says

Executive Summary

A subgroup analysis of Allergan/ISTA's Vitrase data could provide additional evidence for efficacy of the ophthalmic drug for treatment of vitreous hemorrhage, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee said March 17

You may also be interested in...



ISTA Vitrase Spreading Agent Clears FDA; Full Launch Awaits New Vial

ISTA Pharmaceuticals will delay full-scale launch of its spreading agent Vitrase until it receives approval for a more convenient vial form

ISTA Vitrase Spreading Agent Clears FDA; Full Launch Awaits New Vial

ISTA Pharmaceuticals will delay full-scale launch of its spreading agent Vitrase until it receives approval for a more convenient vial form

Vitrase “approvable”

Allergan/ISTA Vitrase "approvable" for vitreous hemorrhage treatment (ovine hyaluronidase), FDA letter says. "FDA requested additional analysis of the existing data and an additional confirmatory clinical study based upon that analysis," ISTA said. FDA's Dermatologic & Ophthalmic Drugs Advisory Committee determined in March that existing data did not demonstrate efficacy, but said ISTA could analyze subgroups and effects on vision for further evidence of efficacy (1"The Pink Sheet" March 24, p. 33). "FDA also cited issues related to the drug substance and drug specifications," company said. FDA did not note any deficiencies in safety data, ISTA added...

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel